Ribomic News

Ribomic: Notice of video distribution of the financial results briefing for the 2nd quarter (interim period) of the fiscal year ending 2025/3

Nov 27 14:30

Ribomic: Financial results briefing for the 2nd quarter (interim period) of the fiscal year ending 2025/3 (Q & A)

Nov 22 14:30

Ribomic: Financial results briefing materials for the 2nd quarter (interim period) of the fiscal year ending 2025/3

Nov 20 17:00

Ribomic: Notice of patent assessment in Taiwan for application patents relating to umedaptanib pegol (anti-FGF2 aptamer)

Nov 19 14:30

Ribomic: Notice regarding presentation of research results for quantum and AI next-generation drug discovery

Nov 15 14:30

Ribomic: Notice of MOU signing with King Abdullah International Medical Research Center

Nov 13 14:30

Ribomic: Confirmatory letter.

Nov 13 09:14

Ribomic: Half Year Report - Term 22 (2024/04/01 - 2025/03/31)

Nov 13 09:13

Ribomic: Notice regarding the recording of non-operating income (grant revenue) and non-operating losses (exchange losses)

Nov 12 14:30

Ribomic: Summary of Non-Consolidated Financial Results for the Six Months Ended September 30 2024(Based on Japanese GAAP)

Nov 12 14:30

Ribomic: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending 2025/3 [Japanese GAAP] (unconsolidated)

Nov 12 14:30

Ribomic: Notice of confirmation of remarkable effects (increase in growth rate) in the low dose group in early phase II clinical trials for achondroplasia (umedaptanib pegol)

Nov 5 14:30

Ribomic: Notice regarding the monthly exercise status of the 17th Stock Acquisition Rights (with exercise price amendment clause)

Nov 1 14:00

Ribomic: Announcement of invited talks at The Riyadh Global Medical Biotechnology Summit

Oct 24 14:00

Ribomic: Presentation materials at the International Skeletal Dysplasia Society international conference

Sep 25 14:00

Ribomic: Notice of NEDO's “Cyber-Physical Development Project for Quantum-Classical Hybrid Technology” Stage Gate Examination Passed

Sep 24 14:00

Ribomic: Presentation materials at The Retina Society international conference

Sep 18 14:00

Ribomic: Notice of European Patent Registration for Formulation Patents Related to umedaptanib pegol (anti-FGF2 aptamer)

Sep 13 11:00

Ribomic: Notice regarding the monthly exercise status of the 17th Stock Acquisition Rights (with exercise price amendment clause)

Sep 2 14:00

Ribomic: Change Report

Aug 28 13:07